Rho/Rho-kinase and C-reactive protein relationship in hypertension and atherosclerosis [12]

Nephrology Dialysis Transplantation

Volumn 21, Issue 4, 2006, Pages 1131-1132

  Calò, Lorenzo A ^a   Pagnin, Elisa ^a   Mussap, Michele ^a   Davis, Paul A ^b   Semplicini, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOSIN II; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO FACTOR; RHO KINASE;

ATHEROSCLEROSIS; BARTTER SYNDROME; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GITELMAN SYNDROME; HUMAN; HYPERTENSION; LETTER; MOLECULAR MECHANICS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; ATHEROSCLEROSIS; BARTTER SYNDROME; C-REACTIVE PROTEIN; HUMANS; HYPERTENSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SYNDROME;

EID: 33645286742     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi272     Document Type: Letter

References (26)

1. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38: 1307-1310
2. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002; 80: 629-638
3. Higashi M, Hiroki J, Hattori T et al. Long-term inhibition of Rhokinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767-775
4. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57-62
5. Takeda K, Ichiki T, Tokunou T et al. Critical role of Rho-kinase and MEK-ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21: 868-873
6. Eto Y, Shimokawa H, Hiroki J et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol 2000; 278: H1744-H1750
7. Wolfrum S, Dendorfer A, Rikitake Y et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3 kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24: 1842-1847
8. Nakakuki T, Ito M, Iwasaki H et al. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25: 2088-2093
9. Calò L, Davis PA, Semplicini A. Regulation of vascular tone in Bartter's and Gitelman's syndromes. Crit Rev Clin Lab Sci 2000; 37: 503-523
10. Calò LA, Pessina AC, Semplicini A. Angiotensin II signaling in the Bartter's and Gitelman's syndromes, a negative human model of hypertension. High Blood Press Cardiovasc Prev 2005; 12: 17-26
11. Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Calò LA. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: Relationship to angiotensin II signaling. J Hypertens 2004; 22: 1963-1969
12. Pagnin E, Semplicini A, Sartori M, Pessina AC, Calò LA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes relevance for the pathophysiology of hypertension. Am J Hypertens 2005; 18: 1200-1205
13. Calò L, Davis PA, Semplicini A. Bartter's/Gitelman's syndrome: A model for the relationships between hypertension, angiotensin II, oxidative stress and remodeling. Clin Nephrol 2003; 59: 393-394
14. Calò LA, Pagnin E, Davis PA et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89: 4153-4157
15. Calò L, Ceolotto G, Milani M et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60: 882-889
16. Calò L, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: Relationship with vascular hyporeactivity. Kidney Int 2002; 61: 353-354
17. Di Virgilio F, Calò L, Cantaro S, Favaro S, Piccoli A, Borsatti A. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. Clin Sci 1987; 72: 483-488
18. Calo L, D'Angelo A, Cantaro S et al. Intracellular calcium signalling and vascular reactivity in Bartter's syndrome. Nephron 1996; 72: 570-573
19. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: Relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18: 1518-1525
20. Calò L, Sartore G, Bassi A et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16: 1001-1008
21. Calò L, Davis PA, Milani M et al. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 1999; 51: 12-17
22. - and cyclic GMP levels in patients with Bartter's syndrome: Relationship to vascular reactivity. Am J Kidney Dis 1996; 27: 874-879
23. Mita S, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens 2005; 23: 87-96
24. Davis PA, Mussap M, Pagnin E, Bertipaglia L, Semplicini A, Calò LA. Early markers of inflammation in a high angiotensin II state. Results of studies in Bartter's/Gitelman's syndromes. J Intern Med 2005 submitted
25. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997; 11: 463-475
26. Segain JP, Raingeard de la Bletiere D, Sauzeau V et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 2003; 124: 1180-1187